Full Text View
Tabular View
No Study Results Posted
Related Studies
The Young Adult and Pediatric Bipolar Study
This study is ongoing, but not recruiting participants.
First Received: July 10, 2006   Last Updated: October 4, 2007   History of Changes
Sponsor: Validus Pharmaceuticals
Information provided by: Validus Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00350857
  Purpose

To examine the safety and effectiveness of extended-release carbamazepine in the treatment of children and adolescents aged 10-17 years with acute manic or mixed bipolar I disorder.


Condition Intervention Phase
Bipolar I Disorder
Drug: Extended-Release Carbamazepine
Phase IV

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Official Title: A Phase IV, Multi-Center, Open-Label, Safety and Effectiveness Study of Extended-Release Carbamazepine in the Treatment of Mania in Children and Adolescents Aged 10-17 Years With Acute Manic or Mixed Bipolar I Disorder.

Resource links provided by NLM:


Further study details as provided by Validus Pharmaceuticals:

Primary Outcome Measures:
  • Safety and tolerability as assessed by the occurrence of treatment emergent adverse events and evaluations of clinical laboratory values, physical examinations, vital signs and ECG data after 6 months of treatment. [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Reduction of bipolar symptoms as assessed by the Young Mania Rating Scale (YMRS), Clinical Global Impressions Scale (CGI) and Children's Depression Rating Scale (CDRS-S) after 6 months of treatment. [ Time Frame: 6 months ]

Estimated Enrollment: 225
Study Start Date: July 2006
Estimated Study Completion Date: May 2008
  Eligibility

Ages Eligible for Study:   10 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Key Inclusion Criteria:

    1. DSM-IV diagnosis of bipolar I disorder, most recent episode manic or mixed.
    2. A lifetime history of bipolar disorder symptoms for at least 2 months.
    3. YMRS score greater than or equal to 16.
    4. CGI-S score greater than or equal to 4.
    5. Male or female outpatient aged between 10-17 years old inclusive at the time of consent.
    6. Functioning at an age-appropriate level intellectually, as deemed by the Investigator.
    7. The subject has no co-morbid illness that could affect efficacy, safety, or tolerability or in any way interfere with the subject's participation in the study.
    8. Must have a satisfactory medical assessment with no clinically significant and relevant abnormalities.

Exclusion Criteria:

  • Key Exclusion Criteria:

    1. Current controlled or uncontrolled, co-morbid psychiatric diagnosis that could interfere with clinical assessments or study conduct.
    2. A history of lack of therapeutic response or hypersensitivity to the study drug.
    3. A greater than or equal to 50% reduction in YMRS between Screening and Baseline.
    4. Acutely at risk for suicidal or violent behavior or a history of suicide attempts requiring medical intervention.
    5. A history of aplastic anemia, agranulocytosis or bone marrow depression.
    6. A history of seizure disorder, other than a single childhood febrile seizure.
    7. A history of severe, unstable asthma.
    8. Current hospitalization for psychiatric symptoms.
    9. History of alcohol or other substance abuse or dependence.
    10. Pregnant or lactating females.
    11. Body weight less than or equal to 25 kg.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00350857

  Show 26 Study Locations
Sponsors and Collaborators
Validus Pharmaceuticals
  More Information

No publications provided

Study ID Numbers: SPD417-311
Study First Received: July 10, 2006
Last Updated: October 4, 2007
ClinicalTrials.gov Identifier: NCT00350857     History of Changes
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Tranquilizing Agents
Disease
Physiological Effects of Drugs
Psychotropic Drugs
Central Nervous System Depressants
Antimanic Agents
Pharmacologic Actions
Pathologic Processes
Carbamazepine
Analgesics, Non-Narcotic
Sensory System Agents
Therapeutic Uses
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents
Anticonvulsants

ClinicalTrials.gov processed this record on February 08, 2010